Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: A 36-month analysis of a phase i and II study

Kensuke Usuki, Arinobu Tojo, Yasuhiro Maeda, Yukio Kobayashi, Akira Matsuda, Kazuma Ohyashiki, Chiaki Nakaseko, Tatsuya Kawaguchi, Hideo Tanaka, Tadashi Nagai, Yasushi Miyazaki, Shinichiro Okamoto, Taro Amagasaki, Kenji Oritani, Aira Wanajo, Masaya Okada, Tomoki Naoe, Koichi Miyamura, Noriko Usui

Research output: Contribution to journalArticlepeer-review

12 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Efficacy and safety of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL: A 36-month analysis of a phase i and II study'. Together they form a unique fingerprint.

Medicine & Life Sciences